Urology
Volume 73, Issue 5, Supplement , Pages S21-S27 , May 2009

Risk of Developing Prostate Cancer in the Future: Overview of Prognostic Biomarkers

  • Neil E. Fleshner

      Affiliations

    • Division of Urology, University Health Network, Toronto, Ontario, Canada
    • Department of Surgery, Division of Urology, University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationReprint requests: Neil Fleshner, M.D., Division of Urology, University Health Network, 610 University Avenue, Room 3-130, Toronto, ON M5G 2M9 Canada
    • ,
  • Nathan Lawrentschuk

      Affiliations

    • Division of Urology, University Health Network, Toronto, Ontario, Canada
    • Department of Surgery, Division of Urology, University of Toronto, Toronto, Ontario, Canada

Received 2 February 2009 ,Accepted 24 February 2009.

  • Image Result

    Predicted probability of advanced prostate cancer using total prostate-specific antigen (PSA) level in anticoagulated plasma measured at age 44-50 years. Dashed lines indicate 95% confidence intervals

    Predicted probability of advanced prostate cancer using total prostate-specific antigen (PSA) level in anticoagulated plasma measured at age 44-50 years. Dashed lines indicate 95% confidence intervals. Reprinted, with permission, from Ulmert et al.18

 N. E. Fleshner serves as a consultant to AstraZeneca, GlaxoSmithKline, Merck, Sanofi-Aventis, Novartis, and Pfizer; he has received grant support for clinical trials from AstraZeneca, GlaxoSmithKline, and Sanofi-Aventis. N. Lawrentschuk has no conflicts to report.

PII: S0090-4295(09)00274-X

doi: 10.1016/j.urology.2009.02.022

Urology
Volume 73, Issue 5, Supplement , Pages S21-S27 , May 2009

Article Tools

* Image Usage & Resolution